SureTrader Advertisement Advertisement
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (BHRTD)

Add BHRTD Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator captainscotty
Search This Board:
Last Post: 11/25/2015 11:27:29 PM - Followers: 168 - Board type: Free - Posts Today: 0


Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


MyoCell SDF-1 



Bioheart’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell.

The MyoCath is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium, the inner wall of the heart. 

Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells.  Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy.  


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
BHRT - Daily Candlesticks


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
BHRT News: Statement of Changes in Beneficial Ownership (4) 11/06/2015 04:02:22 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 11/06/2015 04:01:26 PM
BHRT News: Quarterly Report (10-q) 11/05/2015 04:05:13 PM
BHRT News: Current Report Filing (8-k) 11/04/2015 09:02:01 AM
BHRT News: Statement of Changes in Beneficial Ownership (4) 11/02/2015 09:02:07 AM
#16679  Sticky Note Quote LOL, "This is at Nasadaq price days! Captain Kirk 11/04/15 06:31:39 PM
#16848   The ultra low volume will kill this company. Poor Man - 11/25/15 11:27:29 PM
#16847   Agreed garym 11/25/15 09:48:53 AM
#16846   Murphy's old company founded in 1957 in a Poor Man - 11/24/15 09:10:58 PM
#16845   Ouch that one hurt.... I see that it EquityElite 11/24/15 11:33:33 AM
#16844   Quote BS LOL, "I suggest you read this Captain Kirk 11/24/15 11:25:39 AM
#16843   I suggest you read this and let it EquityElite 11/24/15 11:04:06 AM
#16842   Quote BS LOL, "The way revenues are heading Captain Kirk 11/24/15 10:14:49 AM
#16841   One being the gov IMO EquityElite 11/24/15 09:54:34 AM
#16840   Mike Tomas is fortunate t have supporters toddski 11/24/15 09:48:12 AM
#16839   In who's lifetime? Poor Man - 11/24/15 07:53:07 AM
#16838   The way revenues are heading debt could be EquityElite 11/24/15 07:44:00 AM
#16837   WOW DOGGY Poor Man - 11/23/15 09:29:20 PM
#16836   POS looks like it flat-lined on the table, Captain Kirk 11/23/15 06:49:29 PM
#16835   Abnormal volume today IMO EquityElite 11/23/15 02:03:11 PM
#16834   How about USRM tho? EquityElite 11/22/15 08:21:33 PM
#16833   BHRTd is a worthless stock. Poor Man - 11/22/15 07:15:03 PM
#16832   Do we know when the big "D" will EquityElite 11/22/15 09:35:42 AM
#16831   $BHRT "D" Maybe EE...The MC will be so captainscotty 11/21/15 06:36:50 PM
#16830   Have you read any of EquityElite's posts? Gsdubb's? Tfan15 11/21/15 02:41:13 PM
#16829   Have you read any of Captain Kirk's posts? toddski 11/21/15 01:12:17 PM
#16828   To each their own. If you don't want EquityElite 11/21/15 07:45:27 AM
#16827   This is insane. I cannot believe anybody would toddski 11/20/15 09:35:24 PM
#16826   Well we kept asking for a rise in EquityElite 11/20/15 08:03:51 PM
#16825   Amended SC 13 filed, Vis Vires SOLD OUT, Captain Kirk 11/20/15 06:27:31 PM
#16824   What the heck happened? marco polo iii 11/20/15 05:41:16 PM
#16823   Wow it went under a dollar!!! So glad marco polo iii 11/20/15 05:40:29 PM
#16822   Looks like we got a winner winner chicken EquityElite 11/20/15 12:27:08 PM
#16821   I think I just saw a rock move! EquityElite 11/20/15 12:03:04 PM
#16820   Any volume today or is my screen froze? EquityElite 11/20/15 11:17:01 AM
#16819   BMAK off the Ask, Form-4 buy prop-it-up IMO Captain Kirk 11/20/15 10:06:37 AM
#16818   Zero-Share Trading Pattern Forming Poor Man - 11/20/15 09:47:48 AM
#16817   Lookin good here. Ready for da bounce! IMO EquityElite 11/20/15 08:38:11 AM
#16816   The chart shows more dilution. Poor Man - 11/19/15 07:42:23 PM
#16815   Very bullish chart IMO. Bottomed out 3 days EquityElite 11/19/15 06:48:56 PM
#16814   Has the market spoken or confused with this one? EquityElite 11/19/15 03:35:24 PM
#16813   Just went MEGA SPREAD, looks like Form-4 buy, Captain Kirk 11/19/15 11:43:59 AM
#16812   Quote LOL, "Why hasn't CEO bought shares at Captain Kirk 11/19/15 11:32:00 AM
#16811   Could this break .7 today?? EquityElite 11/19/15 10:47:17 AM
#16810   Why hasn't CEO bought shares at these ultra EquityElite 11/19/15 10:13:45 AM
#16809   Very Deceptive!!! Poor Man - 11/19/15 08:14:07 AM
#16808   Quote, "Do you think a medical staff of Captain Kirk 11/18/15 11:52:14 PM
#16807   This company reports less revenue than a Burger King. Poor Man - 11/18/15 11:23:54 PM
#16806   While you were on the site I hope andyshow 11/18/15 11:20:36 PM
#16805   Great Mystery... Poor Man - 11/18/15 11:17:47 PM
#16804   Other than one person... Poor Man - 11/18/15 11:07:34 PM
#16803   Do you think a medical staff of 6 andyshow 11/18/15 10:39:03 PM
#16802   Wonder if she also files the 10Qs that Poor Man - 11/18/15 10:21:39 PM
#16801   Well then she must live here: US StemCell andyshow 11/18/15 09:37:10 PM
#16800   No big news. Poor Man - 11/18/15 09:17:42 PM
#16799   Agreed, this is a marathon not a sprint. EquityElite 11/18/15 09:10:29 PM